Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | GAA | P10253 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 3/20 | 0.38 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6783336 | 0.84 | KDM4E (0.56) | KDM4EALDH1A1GAAKMT2AHPGD | |
| SCHEMBL6790901 | 0.76 | KDM4E (0.56) | KDM4EALDH1A1GAAKMT2AHPGD | |
| SCHEMBL6783637 | 0.73 | KDM4E (0.70) | KDM4EALDH1A1GAAKMT2AHPGD | |
| SCHEMBL6785609 | 0.71 | ALDH1A1 (0.61) | KDM4EALDH1A1GAAKMT2AHPGD | |
| SCHEMBL29642712 | 0.70 | KDM4E (0.74) | KDM4EALDH1A1GAAKMT2AHPGD | |
| SCHEMBL6783544 | 0.70 | KDM4E (0.74) | KDM4EALDH1A1GAAKMT2AHPGD | |
| SCHEMBL6781147 | 0.69 | KDM4E (0.94) | KDM4EALDH1A1GAAKMT2AHPGD | |
| Trifluoromethanesulfonic Acid SCHEMBL1110858 | 0.66 | SRD5A2 (0.38) | SMN1; SMN2POLB | |
| SCHEMBL6780160 | 0.65 | KDM4E (0.58) | KDM4EALDH1A1GAAKMT2AHPGD | |
| SCHEMBL6780670 | 0.64 | KMT2A (0.53) | KDM4EALDH1A1GAAKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3056509-A1 | BOMBESIN ANALOGUES FOR USE IN DIAGNOSIS | Piramal Imaging SA (CH) | 2016-08-17 | — | — | EP | disclosed |
| EP-2455105-B1 | Bombesin analogues | PIRAMAL IMAGING SA (CH) | 2016-02-17 | — | — | EP | disclosed |
| EP-2063918-B1 | COMPOUNDS AND METHODS FOR 18F LABELED AGENTS | PIRAMAL IMAGING SA (CH) | 2014-02-26 | — | — | EP | disclosed |
| US-8557776-B2 | Compounds and methods for 18F labeled agents | Bayer Pharma AG (DE) | 2013-10-15 | — | — | US | disclosed |
| EP-2455105-A2 | Bombesin analogues | Bayer Pharma Aktiengesellschaft (DE) | 2012-05-23 | — | — | EP | disclosed |
| EP-2289564-A2 | Derivatives of aniline as precursors for F18-labeling | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-03-02 | — | — | EP | disclosed |
| EP-2279759-A2 | Compounds and methods for 18F labeled agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-02-02 | — | — | EP | disclosed |
| EP-2063918-A2 | COMPOUNDS AND METHODS FOR 18F LABELED AGENTS | Bayer Schering Pharma AG (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-20080292548-A1 | COMPOUNDS AND METHODS FOR 18F LABELED AGENTS | Lantheus Biosciences Ltd. (GB) | 2008-11-27 | — | — | US | disclosed |
| WO-2008028688-A2 | COMPOUNDS AND METHODS FOR 18F LABELED AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292548-A1 | COMPOUNDS AND METHODS FOR 18F LABELED AGENTS | QPCT, GBA2, GBA1 | KDM4E 2022/4885ALDH1A1 2019/4885GAA 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.